Introduction into PPPM as a new paradigm of public health service: an integrative view

EPMA Journal

Sergey V Suchkov⁶  Mikhail A Paltsev¹  Paolo Pozzilli⁷  Michael Legg²  Maria O Bocharova⁵  Dmitry A Gnatenko⁵  Shimon Slavin⁴  Elena N Antonova⁵  Dmitry S Kostyushev⁵  Tatiana A Bodrova³ 

[1] National Research Centre Kurchatov Institute, Moscow, Russia;Centre for Health Informatics, Sydney, Australia;National Research University ‘Higher School of Economics’, Moscow, Russia;The International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Weizman Center, Israel;I.M.Sechenov First Moscow State Medical University, Moscow, Russia;Moscow State Medical Dental University, Moscow, Russia;Department of Endocrinology and Diabetes, Rome University, Rome, Italy

关键词: Integrative medical approach;    Economy;    Legacy;    Policy;    Ethics;    Biomarkers;    Biopredictors;    Bioinformatics;    Omics;    Subclinical;    and personalised medicine;    preventive;    Predictive;   

Others  :  801973
DOI  :  10.1186/1878-5085-3-16

 received in 2012-10-06, accepted in 2012-10-16,  发布年份 2012

【 摘 要 】

In the present state of healthcare, usual medical care is generally given to the already diseased person, while the key link—personal health monitoring underlain by predictive, preventive, and personalised medicine (PPPM) techniques that are being intensively elaborated worldwide—is simply missing. It is this link, based on the recognition of subclinical conditions, prediction, and further preventive measures, that is capable of regulating morbidity and diminishing the rates of disability among able-bodied population, thus significantly cutting the traditionally high costs of treating the already diseased people. To achieve the above-mentioned goal—the elaboration of the PPPM concept and its practical implementation—it is necessary to create a fundamentally new strategy based upon the subclinical recognition of the signs—bioindicators of cryptic abnormalities long before the disease clinically manifests itself. The implementation of PPPM programme requires an adjusted technology for the proper interpretation of diagnostic data, which would allow for the current ‘physician-patient’ model to be gradually replaced by a novel model, ‘medical advisor-healthy men-at-risk’. This is the reason for an additional need in organising combinatorial scientific, clinical, training and educational projects in the area of PPPM to elicit the content of this new branch of medicine.

【 授权许可】

   
2012 Bodrova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 11.

Figure 12.

【 参考文献 】

• [1]Ray R: The future of medicine. Am J Med 2012, 125(3):236-239.
• [2]Costigliola V, Gahan P, Golubnitschaja O: Predictive medicine as the new philosophy in healthcare. In Predictive Diagnostics and Personalized Treatment: Dream or Reality. Edited by Golubnitschaja O. New York: Nova Science Publishers; 2009:1-3.
• [3]Golubnitschaja O, Costigliola V: European strategies in predictive, preventive and personalised medicine: highlights of the EPMA World Congress. EPMA J 2011, 2(4):315-332.
• [4]Golubnitschaja O: Time for new guidelines in advanced healthcare: the mission of The EPMA Journal to promote an integrative view in predictive, preventive and personalized medicine. EPMA J 2012, 3:5.
• [5]Golubnitschaja O, Costigliola V: Common origin but individual outcomes: time for new guidelines in personalised healthcare. Personalized Med 2010, 7(5):561-568.
• [6]Jones T, Price P: Development and experimental medicine applications of PET in oncology: a historical perspective. Lancet Oncol 2012, 13:e116-e125.
• [7]Patel NR, McPhail MJ, Shariff MI, Keun HC, Taylor-Robinson SD: Biofluid metabonomics using (1)H NMR spectroscopy: the road to biomarker discovery in gastroenterology and hepatology. Expert Rev Gastroenterol Hepatol 2012, 6:239-251.
• [8]Hood L, Balling R, Auffray C: Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J 2012, 7:992-1001.
• [9]Golubnitschaja O, Yeghiazaryan K, Cebioglu M, Morelli M, Herrera-Marschitz M: Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. EPMA J 2011, 2(2):197-210.
• [10]Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL: Cancer genomics: technology, discovery, and translation. J Clin Oncol 2012, 30(6):647-660.
• [11]Scott SA: Personalizing medicine with clinical pharmacogenetics. Genet Med 2011, 13(12):987-995.
• [12]Ahearn JM, Liu CC, Kao AH, Manzi S: Biomarkers for systemic lupus erythematosus. Transl Res 2012, 159(4):326-342.
• [13]Nair VS, Maeda LS, Ioannidis JP: Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012, 104(7):528-540.
• [14]Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H: The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012, 58(5):837-845.
• [15]Anbalagan M, Huderson B, Murphy L, Rowan BG: Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal 2012, 10:e001.
• [16]Iskandar HN, Ciorba MA: Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012, 159(4):313-325.
• [17]Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, Grobbee DE: Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 2012, 98(9):683-690.
• [18]Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, Woodward M: Risk prediction models: II. External validation, model updating, and impact assessment. Heart 2012, 98(9):691-698.
• [19]Wilkins JT, Lloyd-Jones DM: Are novel serum biomarkers informative? Med Clin North Am 2012, 96(1):1-11.
• [20]Saubermann AJ, Lagasse RS: Prediction of rate and severity of adverse perioperative outcomes: “normal accidents” revisited. Mt Sinai J Med 2012, 79(1):46-55.
• [21]Lemke HU, Berliner L: Patient specific modeling and model guided therapy. EPMA J 2011, 2(Supplement 1):181-182.
• [22]Farra N, Manickaraj AK, Ellis J, Mital S: Personalized medicine in the genomics era: highlights from an international symposium on childhood heart disease. Future Cardiol 2012, 8(2):157-160.
• [23]Pozgar George D: Legal Aspects of Health Care Administration. 10th edition. Chapter 21. New York: Jones & Bartlett Publishers; 2007.
• [24]Grundy SM: Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012, 59(7):635-643.
• [25]Lejbkowicz I, Caspi O, Miller A: Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis. Expert Rev Neurother 2012, 12(3):343-352.
• [26]Khitrov AN, Shogenov ZS, Tretyak EB, Ischenko AI, Matsuura E, Neuhaus O, Paltsev MA, Suchkov SV: Postinfectious immunodeficiency and autoimmunity: pathogenic and clinical values and implications. Expert Rev Clin Immunol 2007, 3(3):323-331.
• [27]Jain KK: Role of nanodiagnostics in personalized cancer therapy. Clin Lab Med 2012, 32(1):15-31.
• [28]Belogurov AA Jr, Kurkova IN, Friboulet A, Thomas D, Misikov VK, Zakharova MY, Suchkov SV, Kotov SV, Alehin AI, Avalle B, Souslova EA, Morse HC 3rd, Gabibov AG, Ponomarenko NA: Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol 2008, 180(2):1258-1267.
• [29]Huang Y, Mucke L: Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148(6):1204-1222.
• [30]Costigliola V (Ed): Healthcare Overview: New Perspectives. Dordrecht, Heidelberg, New York, London: Springer; 2012. [O Golubnitschaja O (Series Editor) Advances in Predictive, Preventive and Personalised Medicine.]
• [31]Robinton DA, Daley GQ: The promise of induced pluripotent stem cells in research and therapy. Nature 2012, 481(7381):295-305.
• [32]Midorikawa Y, Tsuji S, Takayama T, Aburatani H: Genomic approach towards personalized anticancer drug therapy. Pharmacogenomics 2012, 13(2):191-199.
• [33]Sheiman I, Shishkin S: New challenges and new objectives problems of economic transition. Russian Health Care 2010, 52(12):4-49.
• [34]Mossialos E, Monique Mrazek M, Tom Walley T: Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. In European Observatory on Health Systems and Policies Series. Berkshire: Open University Press; 2004.
• [35]Henderson J: Health Economics and Policy. Cincinnati: South-Western College Publishing; 1999:1-30. 290–321, 378–414